194 related articles for article (PubMed ID: 34551960)
1. Computational Analysis of Cholangiocarcinoma Phosphoproteomes Identifies Patient-Specific Drug Targets.
Khorsandi SE; Dokal AD; Rajeeve V; Britton DJ; Illingworth MS; Heaton N; Cutillas PR
Cancer Res; 2021 Nov; 81(22):5765-5776. PubMed ID: 34551960
[TBL] [Abstract][Full Text] [Related]
2. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
3. The cyclin‑dependent kinase pathway involving CDK1 is a potential therapeutic target for cholangiocarcinoma.
Yamamura M; Sato Y; Takahashi K; Sasaki M; Harada K
Oncol Rep; 2020 Jan; 43(1):306-317. PubMed ID: 31746435
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines.
Dokduang H; Jamnongkarn W; Promraksa B; Suksawat M; Padthaisong S; Thanee M; Phetcharaburanin J; Namwat N; Sangkhamanon S; Titapun A; Khuntikeo N; Klanrit P; Loilome W
Drug Des Devel Ther; 2020; 14():2319-2334. PubMed ID: 32606601
[TBL] [Abstract][Full Text] [Related]
5. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
6. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
[TBL] [Abstract][Full Text] [Related]
7. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
9. Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma.
Braconi C; Swenson E; Kogure T; Huang N; Patel T
PLoS One; 2010 Dec; 5(12):e15195. PubMed ID: 21179572
[TBL] [Abstract][Full Text] [Related]
10. Patient-Derived Organoids of Cholangiocarcinoma.
Maier CF; Zhu L; Nanduri LK; Kühn D; Kochall S; Thepkaysone ML; William D; Grützmann K; Klink B; Betge J; Weitz J; Rahbari NN; Reißfelder C; Schölch S
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445380
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells in cholangiocarcinoma (Review).
Mcgrath NA; Fu J; Gu SZ; Xie C
Int J Oncol; 2020 Aug; 57(2):397-408. PubMed ID: 32468022
[TBL] [Abstract][Full Text] [Related]
12. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
13. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Zhang Z; Oyesanya RA; Campbell DJ; Almenara JA; Dewitt JL; Sirica AE
Hepatology; 2010 Sep; 52(3):975-86. PubMed ID: 20607690
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
15. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
Huang M; Huang B; Li G; Zeng S
BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors.
Ewald F; Nörz D; Grottke A; Hofmann BT; Nashan B; Jücker M
Invest New Drugs; 2014 Dec; 32(6):1144-54. PubMed ID: 25152244
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
18. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
19. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M
Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426
[No Abstract] [Full Text] [Related]
20. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
